Cargando…
216. A Comparison of Multidrug-Resistant Gram-negative Bacteremia in Cancer and Non-Cancer Patients
BACKGROUND: Multidrug-resistant gram-negative bacteremia (MDR-GNB) is a growing threat worldwide as it is associated with increased morbidity and mortality. We sought to describe the clinical features of MDR-GNB and outcomes in cancer and non-cancer Pts. METHODS: We performed a retrospective study o...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677187/ http://dx.doi.org/10.1093/ofid/ofad500.289 |
_version_ | 1785150070877847552 |
---|---|
author | Haris Khan, Muhammad Munshi, Ruhul Wangjam, Tamna Bhuiyan, Mohammad Alfrad Nobel Self, Michelle Alam, Mohammad Malek, Alexandre E |
author_facet | Haris Khan, Muhammad Munshi, Ruhul Wangjam, Tamna Bhuiyan, Mohammad Alfrad Nobel Self, Michelle Alam, Mohammad Malek, Alexandre E |
author_sort | Haris Khan, Muhammad |
collection | PubMed |
description | BACKGROUND: Multidrug-resistant gram-negative bacteremia (MDR-GNB) is a growing threat worldwide as it is associated with increased morbidity and mortality. We sought to describe the clinical features of MDR-GNB and outcomes in cancer and non-cancer Pts. METHODS: We performed a retrospective study of adult patients with MDR-GNB at the Ochsner LSU Health Shreveport between January 2018 and July 2022. We collected patients' demographics, medical comorbidities, cancer diagnosis, causative bacteria (MDROs), source of bacteremia, antibiotics therapy, and clinical outcomes. RESULTS: We identified 112 Pts with MDR-GNB. Pts were divided into 2 groups: cancer group (n=33, 29%) and non-cancer group (n=79, 71%). In the cancer group, the majority of Pts had solid tumors (n=20, 61%) vs liquid tumors (n=13, 39%). Mean age was 69 y in cancer compared to 57 y in the non-cancer group. Enterobacteriaceae were isolated in 28 cancer Pts (85%) including ESBL E. coli in 20 Pts (61%), Klebsiella s.p (CRE/ESBL) in 5 Pts (15%), and ESBL P. mirabilis in 3 Pts (9%). Pseudomonas aeruginosa CRO in 3 Pts (9%) and A. baumannii in 2 Pts (6%). In non-cancer Pts, Enterobacteriaceae were isolated in 65 Pts (82%) including ESBL E. coli in 40 Pts (51%), Klebsiella s.p (CRE/ESBL) in 18 Pts (23%) and ESBL P. mirabilis in 6 Pts (8%). P. aeruginosa CRO found in 6 Pts (8%) and A. baumannii in 8 Pts (10%). The sources of bacteremia in cancer group were UTI in 14 Pts (42.4%), osteoarticular infection (OAI) in 5 Pts (15%), pneumonia in 3 Pts (9%), CLABSI in 2 Pts (6%), endovascular in 1 Pt (3%) and unknown in 8 Pts (24%), whereas in non-cancer group, UTI was reported in 40 Pts (68%), pneumonia in 9 (27%), OAI in 1 (1.3%), endocarditis in 1 Pt (1.3%), and unknown in 20 Pts (25.3%). Mean duration of targeted antibiotics was 9 days in cancer vs 13.3 days in non-cancer group (p-value=0.4). Mean length of hospital stay was comparable, 34 d in cancer vs 31 d in non-cancer(p-value= 0.87). 9 Pts were admitted to ICU in cancer group (27%) vs 39 Pts (49%). Mortality rate was 39% in cancer (8 pts went to hospice) vs 16.4% in non-cancer. CONCLUSION: Our data showed that the common source of MDR-GNB remains urinary tract infection in both groups and the bacterial epidemiology is comparable between the two groups. Further studies are warranted to assess the impact of resistant organisms on cancer Pts. DISCLOSURES: All Authors: No reported disclosures |
format | Online Article Text |
id | pubmed-10677187 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-106771872023-11-27 216. A Comparison of Multidrug-Resistant Gram-negative Bacteremia in Cancer and Non-Cancer Patients Haris Khan, Muhammad Munshi, Ruhul Wangjam, Tamna Bhuiyan, Mohammad Alfrad Nobel Self, Michelle Alam, Mohammad Malek, Alexandre E Open Forum Infect Dis Abstract BACKGROUND: Multidrug-resistant gram-negative bacteremia (MDR-GNB) is a growing threat worldwide as it is associated with increased morbidity and mortality. We sought to describe the clinical features of MDR-GNB and outcomes in cancer and non-cancer Pts. METHODS: We performed a retrospective study of adult patients with MDR-GNB at the Ochsner LSU Health Shreveport between January 2018 and July 2022. We collected patients' demographics, medical comorbidities, cancer diagnosis, causative bacteria (MDROs), source of bacteremia, antibiotics therapy, and clinical outcomes. RESULTS: We identified 112 Pts with MDR-GNB. Pts were divided into 2 groups: cancer group (n=33, 29%) and non-cancer group (n=79, 71%). In the cancer group, the majority of Pts had solid tumors (n=20, 61%) vs liquid tumors (n=13, 39%). Mean age was 69 y in cancer compared to 57 y in the non-cancer group. Enterobacteriaceae were isolated in 28 cancer Pts (85%) including ESBL E. coli in 20 Pts (61%), Klebsiella s.p (CRE/ESBL) in 5 Pts (15%), and ESBL P. mirabilis in 3 Pts (9%). Pseudomonas aeruginosa CRO in 3 Pts (9%) and A. baumannii in 2 Pts (6%). In non-cancer Pts, Enterobacteriaceae were isolated in 65 Pts (82%) including ESBL E. coli in 40 Pts (51%), Klebsiella s.p (CRE/ESBL) in 18 Pts (23%) and ESBL P. mirabilis in 6 Pts (8%). P. aeruginosa CRO found in 6 Pts (8%) and A. baumannii in 8 Pts (10%). The sources of bacteremia in cancer group were UTI in 14 Pts (42.4%), osteoarticular infection (OAI) in 5 Pts (15%), pneumonia in 3 Pts (9%), CLABSI in 2 Pts (6%), endovascular in 1 Pt (3%) and unknown in 8 Pts (24%), whereas in non-cancer group, UTI was reported in 40 Pts (68%), pneumonia in 9 (27%), OAI in 1 (1.3%), endocarditis in 1 Pt (1.3%), and unknown in 20 Pts (25.3%). Mean duration of targeted antibiotics was 9 days in cancer vs 13.3 days in non-cancer group (p-value=0.4). Mean length of hospital stay was comparable, 34 d in cancer vs 31 d in non-cancer(p-value= 0.87). 9 Pts were admitted to ICU in cancer group (27%) vs 39 Pts (49%). Mortality rate was 39% in cancer (8 pts went to hospice) vs 16.4% in non-cancer. CONCLUSION: Our data showed that the common source of MDR-GNB remains urinary tract infection in both groups and the bacterial epidemiology is comparable between the two groups. Further studies are warranted to assess the impact of resistant organisms on cancer Pts. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10677187/ http://dx.doi.org/10.1093/ofid/ofad500.289 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Haris Khan, Muhammad Munshi, Ruhul Wangjam, Tamna Bhuiyan, Mohammad Alfrad Nobel Self, Michelle Alam, Mohammad Malek, Alexandre E 216. A Comparison of Multidrug-Resistant Gram-negative Bacteremia in Cancer and Non-Cancer Patients |
title | 216. A Comparison of Multidrug-Resistant Gram-negative Bacteremia in Cancer and Non-Cancer Patients |
title_full | 216. A Comparison of Multidrug-Resistant Gram-negative Bacteremia in Cancer and Non-Cancer Patients |
title_fullStr | 216. A Comparison of Multidrug-Resistant Gram-negative Bacteremia in Cancer and Non-Cancer Patients |
title_full_unstemmed | 216. A Comparison of Multidrug-Resistant Gram-negative Bacteremia in Cancer and Non-Cancer Patients |
title_short | 216. A Comparison of Multidrug-Resistant Gram-negative Bacteremia in Cancer and Non-Cancer Patients |
title_sort | 216. a comparison of multidrug-resistant gram-negative bacteremia in cancer and non-cancer patients |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677187/ http://dx.doi.org/10.1093/ofid/ofad500.289 |
work_keys_str_mv | AT hariskhanmuhammad 216acomparisonofmultidrugresistantgramnegativebacteremiaincancerandnoncancerpatients AT munshiruhul 216acomparisonofmultidrugresistantgramnegativebacteremiaincancerandnoncancerpatients AT wangjamtamna 216acomparisonofmultidrugresistantgramnegativebacteremiaincancerandnoncancerpatients AT bhuiyanmohammadalfradnobel 216acomparisonofmultidrugresistantgramnegativebacteremiaincancerandnoncancerpatients AT selfmichelle 216acomparisonofmultidrugresistantgramnegativebacteremiaincancerandnoncancerpatients AT alammohammad 216acomparisonofmultidrugresistantgramnegativebacteremiaincancerandnoncancerpatients AT malekalexandree 216acomparisonofmultidrugresistantgramnegativebacteremiaincancerandnoncancerpatients |